ROCHESTER, NY--(Marketwired - Apr 16, 2013) - NaturalNano, Inc. (OTCBB: [ NNAN ]) ([ www.naturalnano.com ]) announced that Dr. Michael King, of Cornell University, published his most recent study featuring the use of NaturalNano's Halloysite Natural Tubes (HNT) in Journal of Nanomaterials ([ http://www.hindawi.com/journals/jnm/si/895020/ ]).

The Study demonstrated that the capture of circulating tumor cells (CTCs) in blood can be targeted more effectively by the incorporation of HNT onto the surface of devices used for the capture of CTCs in blood. King's Lab has been developing new methods for the isolation of intact, viable cancer cells from patient blood, based on the physiological adhesion of selectin proteins in micro-scale flow devices.

Here is a link to the freely accessible paper:

[ http://www.hindawi.com/journals/jnm/2012/831263/ ]

Dr. King, a Professor of Biomedical Engineering at Cornell University, states, "The ability to create stable coatings of HNT using an extremely thin layer of poly-L-lysine allows the creation of nanostructured surfaces to which living cells respond. The Microtubes with HNT incorporated onto their surface were found to enhance the natural CTC's rolling mechanism allowing the target cells to be exposed to specific therapeutic agents or isolated and collected for diagnostic and research purposes."

James Wemett, NaturalNano CEO, said, "We are pleased to have our HNT technology used in Dr. King's important work and to be featured in the Journal of Nanomaterials. We look forward to the further use of HNT in medical applications."

NaturalNano, Inc. (OTCBB: [ NNAN ]) is a materials science company focused on developing and commercializing advanced nanocomposites. The Company is focused on additive technologies and processes, including its proprietary Pleximer that adds value to industrial polymers, plastics and composites. NaturalNano holds and/or licenses 10 patents and applications relating to Halloysite, as well as proprietary know-how for its extraction and separation processes, compositions, and derivatives. [ www.naturalnano.com ]

Cautionary Statement Regarding Forward-Looking Statements: Contains forward-looking statements regarding future events and future performance that involve risks and uncertainties that could materially affect actual results. This information is qualified in its entirety by cautionary statements and risk factors disclosure contained in certain of NaturalNano's filings with the Securities and Exchange Commission. The most recent annual reports on Form 10-K and quarterly reports on Form 10-Q filed by NaturalNano provide information about these factors, which may be revised or supplemented in future reports to the SEC on those forms or on Form 8-K. We caution investors not to place undue reliance on forward-looking statements, and we do not undertake any obligation to update or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other such factors that affect the subject of these statements, except where expressly required by law.